{"id":"ari-3037mo","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL5435518","moleculeType":null,"molecularWeight":"356.81"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARI-3037MO works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.","oneSentence":"ARI-3037MO is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:07.649Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02574325","phase":"PHASE2","title":"A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis","status":"UNKNOWN","sponsor":"Arisaph Pharmaceuticals Inc","startDate":"2015-10","conditions":"Nonalcoholic Steatohepatitis","enrollment":11},{"nctId":"NCT02250105","phase":"PHASE2","title":"Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia","status":"COMPLETED","sponsor":"Arisaph Pharmaceuticals Inc","startDate":"2014-09","conditions":"Hypertriglyceridemia","enrollment":80},{"nctId":"NCT02532218","phase":"PHASE2","title":"Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia","status":"UNKNOWN","sponsor":"Arisaph Pharmaceuticals Inc","startDate":"2015-08","conditions":"Hyperlipidemia","enrollment":176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ARI-3037MO","genericName":"ARI-3037MO","companyName":"Arisaph Pharmaceuticals Inc","companyId":"arisaph-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ARI-3037MO is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}